Human Immunodeficiency Virus Clinical Trial
Official title:
Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique
This is a prospect, randomized control trial to evaluate merits between flip and no flip technique in Shang Ring children circumcision.
The boys between 7 and 12 years old seeking for circumcision in The Affiliated Hospital of
Medicine School of Ningbo University will be evaluated. Those who match the inclusion
criteria and without exclusion criteria will be recruited.
The investigators will perform randomization preoperatively. participants were distributed
into No Flip Group and Flip Group correspondingly according to a table of random number.
All of the procedures will be performed by a specific study surgeon in the hospital
operation room. An assistant will take the pictures and recorder the parameters needed. In
both groups, participants will be measured twice by a scale plate of holes, the diameter of
penis with the foreskin noneverted and the diameter of exposed glans. Local anesthesia will
be administered to the dorsal penile nerve using 2% lidocaine. The operation will not begin
until the anesthesia is satisfied. The proper ring will be chosen according to different
strategies of two groups. Participants will stay in hospital for 24 hours after operation.
Pain during operation, half a hour post-operation and 24 hours will be evaluated, adverse
events at hospital will be recorded carefully as well.
Participants will be advised to return usually at 7th, 14th, 21st, 28th and 90th
post-operative days. However, if the wound does not heal completely 28 days
post-operatively, the participant will be asked come to visit weekly until complete healing.
All of the assessments will be performed and recorded by the lead investigator.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |